Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oruka Therapeutics (ORKA)
NASDAQ:ORKA
RESEARCH TOOLSreports
Holding ORKA?
Track your performance easily
ORKA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.20 - $53.88
Previous Close$21.94
Volume529.44K
Average Volume (3M)139.79K
Market Cap
$767.87M
Enterprise Value$734.59M
Total Cash (Recent Filing)$33.28M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Feb 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 29, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-6.68
Shares Outstanding34,998,550
10 Day Avg. Volume201,580
30 Day Avg. Volume139,786
Standard Deviation0.37
R-Squared0.01
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)23.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-72.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-93.92
Forecast
1Y Price Target
$43.00Price Target Upside90.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Oruka Therapeutics News
PremiumCompany Announcements
Oruka Therapeutics: Strong Q3 and Strategic Advances
PremiumCompany Announcements
Oruka Therapeutics Adjusts Executive Severance AgreementsBulls Say, Bears Say
Bulls Say
Financial StabilityThe company ended with $410.9M in cash, which is expected to be sufficient to fund operations through 2027.
Market PotentialBoth candidates have the potential to generate more than $5 billion of peak sales individually, indicating strong market potential.
Product InnovationORKA-001 is an IL-23p19 inhibitor with the potential for twice per year or once per year dosing, significantly improving patient convenience over the current IL-23 SOC Skyrizi.
Bears Say
Clinical DataIcotrokinra data falls below the expected results compared to biologics targeting IL-23p19 and IL-17A/F.
Clinical TrialsInability to advance ORKA-001 and ORKA-002 into pivotal trials in a timely fashion is a significant risk.
Regulatory ApprovalThere is a risk of failure to secure regulatory approval for ORKA-001 and ORKA-002 in major markets.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ORKA FAQ
What was Oruka Therapeutics’s price range in the past 12 months?
Oruka Therapeutics lowest stock price was $18.20 and its highest was $53.88 in the past 12 months.
What is Oruka Therapeutics’s market cap?
Currently, no data Available
When is Oruka Therapeutics’s upcoming earnings report date?
Oruka Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 60 days.
How were Oruka Therapeutics’s earnings last quarter?
Oruka Therapeutics released its earnings results on Nov 13, 2024. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.402 by -$1.058.
Is Oruka Therapeutics overvalued?
According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued.
Does Oruka Therapeutics pay dividends?
Oruka Therapeutics pays a Notavailable dividend of $19.08 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here
What is Oruka Therapeutics’s EPS estimate?
Oruka Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oruka Therapeutics have?
Oruka Therapeutics has 34,998,550 shares outstanding.
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Oruka Therapeutics reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.402. Following the earnings report the stock price went down -6.433%.
Which hedge fund is a major shareholder of Oruka Therapeutics?
Among the largest hedge funds holding Oruka Therapeutics’s share is Fairmount Funds Management Llc. It holds Oruka Therapeutics’s shares valued at 79M.
---
Oruka Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (90.60% Upside)
$43.00 (90.60% Upside)
Blogger Sentiment
Bullish
ORKA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 10.8%
Last 30 Days ▼ 10.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
90.99%
12-Months-Change
Fundamentals
Return on Equity
-15.88%
Trailing 12-Months
Asset Growth
956.78%
Trailing 12-Months
Company Description
Oruka Therapeutics
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.
---
ORKA Stock 12 Month Forecast
Average Price Target
$43.00
▲(90.60% Upside)
Technical Analysis
Axsome Therapeutics
―
Blueprint Medicines
―
EyePoint Pharmaceuticals
―
Fate Therapeutics
―
Best Analysts Covering ORKA
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
+1.45%
reiterated a buy rating 27 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.45% per trade.
---